VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rocketman who wrote (6722)	5/30/1999 8:07:00 PM
From: Andreas Helke	Read Replies (1) of 9719

How about buying back Ligand? I think the substantial investment in research and development that so far have suppressed the stock price will eventually lead to substantial profits in the next few years. And after the Elan deal LGND finally seems to have enough cash to last till profitability. With the awful financing conditions for biotech companies I do now strongly prefer companies that either are profitable or already have enough cash to last to profitability. On the top of my personal buy list (I already have enough or probably too much LGND) are SEPR and especially MOGN. With the current MOGN stock price you essentially get MGI 114 a promising cancer drug candidate for free. Andreas

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next